Hangzhou Tigermed Consulting Co., Ltd. Class H (HK:3347) has released an update.
Hangzhou Tigermed Consulting Co. Ltd. has announced a further change in the use of the proceeds from its H Shares offering, which initially totaled HK$11,817.4 million after expenses. The company aims to allocate these funds towards expanding clinical trial services, acquiring complementary clinical CROs for global expansion, investing in biopharmaceutical R&D, developing advanced technologies, and for working capital and general corporate purposes. These strategic moves are designed to meet increasing demand and to foster growth in both domestic and international markets.
For further insights into HK:3347 stock, check out TipRanks’ Stock Analysis page.
